Indication:

The treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. Deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,Deferasirox is also indicated for the treatment of chronic iron overload in patients with nontransfusion-dependent thalassemia syndromes aged 10 years and older.

Generic Name: Deferasirox

Strength: 90mg

Dosage: FC Tab

Shelflife Months: 36

Pack Size: 30

Tablet Description: Light blue colour, film coated oval shaped biconvex tablets, debossed with 'DFX' on the one side and '90' on other side

Segment :B

Innovator: Jadenu®

PBSListed: Yes

RPBSlisted: No

Schedule: S4

Storage Conditions: Store below 25 degrees Celsius

Active Ingredients: deferasirox 90mg

Warnings: